Propel Bio Management, LLC
CIK: 0001969764Latest portfolio: $117.1M · Q4 2025
Holdings
20
Total Value
$117.1M
New Positions
8
Closed Positions
4
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | PAGPPLAINS GP HLDGS L P | 1,272,360 | $24.4M | 20.79% | — | |
| 2 | SP4PACHIEVE LIFE SCIENCES INC | 3,786,425 | $18.8M | 16.07% | — | |
| 3 | PHATPHATHOM PHARMACEUTICALS INC | 740,918 | $12.3M | 10.49% | +188K | |
| 4 | VRDNVIRIDIAN THERAPEUTICS INC | 282,531 | $8.8M | 7.51% | +193K | |
| 5 | MISTMILESTONE PHARMACEUTICALS | 4,118,321 | $8.3M | 7.10% | -1,006,569 | |
| 6 | KYTXKYVERNA THERAPEUTICS INC | 666,666 | $6.3M | 5.35% | NEW | |
| 7 | CMPSCOMPASS PATHWAYS PLC | 861,778 | $5.9M | 5.08% | +352K | |
| 8 | IVAINVENTIVA SA - ADR | 1,000,000 | $4.7M | 3.97% | NEW | |
| 9 | DCTHDELCATH SYSTEMS INC | 438,509 | $4.4M | 3.78% | — | |
| 10 | ABEOABEONA THERAPEUTICS INC | 830,780 | $4.4M | 3.74% | -143,242 | |
| 11 | TCE2CELLDEX THERAPEUTICS INC | 154,300 | $4.2M | 3.58% | -700 | |
| 12 | NKTRNEKTAR THERAPEUTICS | 82,822 | $3.5M | 2.99% | +34K | |
| 13 | OCSOCULIS HOLDING AG | 172,839 | $3.5M | 2.95% | NEW | |
| 14 | SABSSAB BIOTHERAPEUTICS INC | 652,881 | $2.4M | 2.08% | NEW | |
| 15 | RGNXREGENXBIO INC | 116,896 | $1.7M | 1.44% | NEW | |
| 16 | LONAATHIRA PHARMA INC | 149,279 | $1.1M | 0.96% | — | |
| 17 | LENZLENZ THERAPEUTICS INC | 59,085 | $945K | 0.81% | NEW | |
| 18 | AARDAARDVARK THERAPEUTICS INC | 46,408 | $609K | 0.52% | NEW | |
| 19 | ZVRAZEVRA THERAPEUTICS INC | 63,683 | $570K | 0.49% | -168,191 | |
| 20 | KLRSKALARIS THERAPEUTICS INC | 42,053 | $354K | 0.30% | NEW |
Quarterly Changes
New Positions
Sector Breakdown
Healthcare0.0% ($1.2291879283196267e+55T)
Unknown0.0% ($188.2B)
Energy0.0% ($24.4M)
Filing History
Fund Information
Propel Bio Management, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $117.1M across 20 holdings. The largest position is PLAINS GP HLDGS L P (PAGP), representing 20.8% of the portfolio. Compared to the previous quarter, the fund opened 8 new positions and closed 4 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.